About

Drasys Bio is a company dedicated in designing, developing and manufacturing automated bioreactors for bioprocess research and development in academia and industry. Main bottlenecks in today’s emerging bioprocesses are mainly two: first of all, the lack of suitable bioprocess-specific bioreactor designs that enable easy and efficient scaling from lab to production ,which is easily visible especially in the relatively new field of photosynthetic biotechnology and the environmental biotechnology sector, which translates in bad quality data and subsequent lower profit margins for producers. Secondly, the significant drawback of manually handling data from traditional bioreactors significantly impairs research and development times and adds up cost to laboratories and producers. We provide solution to the first, by utilising our team’s expertise in bioprocess development to design better performing, bioprocess-specific bioreactor configurations and to the second by combining our bioreactors with our bioprocess software which transports data from our bioreactors fleets to a single user interface, available from everywhere.

Solution & Product

We provide integrated solutions to the bioprocess development industry. At Drasys Bio, we combine state of the art bioreactor designs coupled with our bioprocess software that allow our partners in biotechnology accelerate their path to process commercialization through the production of high quality data generated from our parallel-running bioreactor fleets. Bioreactors are running and data is available from a single UI through IoT, wherever you may be. We manufacture our bioreactors and develop our bioprocess software to provide integrated-functional solutions to our customers. We are primarily aiming at the photosynthetic product market for nutraceuticals and cosmetics with our thin-layered photobioreactors, and to the biogas market through our super high viscous anaerobic digestors. Our customers fall in two distinct categories: Academic research laboratories and private companies involved in bioprocess Research & Development. Our target customers are developing bioprocesses for the production of high added value products for the nutraceutical and cosmetics market (astaxanthin, fucoxanthin, poly-unsaturated fatty acids, DHA, EPA) and the renewable energy source market mainly with biogas. We are reaching to our customers mainly through two channels. First, through personalized communication by utilizing our connections in the industry and customer databases that we are continuously developing and product presentation through international biotechnology exhibitions.

Innovation & Scalability

Drasys Bio’s success lie on two main competitive advantages. We conduct business in a market almost inaccessible for those who do not possess deep and vast knowledge on biochemical engineering and bioprocess development and our expertise on the field is backed by years of academic research and a close partnership with laboratory of Biochemical Engineering and Environmental Biotechnology (LBEET) at the Department of Chemical Engineering of University of Patras, Greece. However, our unique value proposition comes by coupling our bioprocess expertise together with state-of-the-art digital technologies implemented from our strong team of software engineers and developers. Not to mention that our integrated bioprocess platform technology allows us to easily expand our market position to new or even established markets (traditional fermentation, cell cultivation, etc). Beginning with our goal of over one hundred thousand euros in revenue by the end of 2021 we are on the path of achieving very high annual growth rates for 2021-2027 in order to achieve 5 million euro in revenue by the end of that period. Company’s potential in annual sales is estimated at about 75 million euros given today’s market value and expected growth rates. Greatest barriers are market hesitation of adopting new technologies due to established procedures and traditions and company’s geographic position in relation to big central and northern European markets.

Traction & achievements

1. Establishment of Drasys Bio. 2. Partnership with Laboratory of Biochemical Engineering and Environmental Technology (LBEET), University Patras to operate & test Drasys Bio’s Bioprocess Platform in real research environment. 3. Certification of ISO 14001 & ISO 9001. 4. Drasys Bio participates in APACT 21’(https://apact.co.uk ) on process analytics and control technology. 5. Client Software alpha version -Testing Alpha version of our client software has finished development stage and will undergo laboratory and field testing until 30/6/2021. Client software is responsible for bioprocess monitoring and control, data storage control and also serves as the User-Bioreactor interface. 6. IoT Bioreactors-Under development This is the bioreactor embedded system responsible for controlling sensors, actors and analytical instruments. Hamilton’s sensor technology is the first sensor technology manufacturer that we will be completely supported by 31/12/2021 7. Anaerobic bioreactors-Under Simulation Testing Bioreactor for anaerobic bioprocesses will be the first Drasys bioreactor in the market. Designed from us, currently undergoes extensive simulation testing. Will be on the market before 30/6/2021

Team & Why Us

Primary Competitive Advantage In biotechnology, every customer is unique and every bioprocess is different. Different cell factories (CF) require different cultivation conditions and different product molecules require unique cultivation environments, unique critical process parameters to control and different process analytical technologies to use. Our goal in Drasys Bio is to provide our customers with all those tools needed to develop tomorrow’s bioprocesses and we make that happen due to our Bioprocess Development Platform Technology which is based on the following principles: • Plug and play any type of bioreactor for any type of bioprocess no matter the scale, the cultivation environment or even the number. • Software integration of the best today available sensor and process analytical technology. • Open connectivity to 3rd party commercial laboratory software (ELN, LIMS), data analytics software. • Cloud based bioreactor monitoring & control. Our platform technology allows us to quickly answer to any need from our customers helping them accelerate their path to production and commercialization by getting deeper insights to their bioprocesses and making better decisions. Secondary Competitive Advantage From design to manufacturing our systems is all Drasys Bio. Our ability to design, test and manufacture our bioreactors based on customer specific needs allows us to adapt to our customer needs while enabling our business scale quickly to emerging biotechnology markets.

Funding Needs

Drasys Bio’s business and revenue model is based on company’s ability to participate in international biotechnology and bioprocess technology and equipment exhibitions. Company’s goal is to participate at least in two such events every year particularly focusing in the following events: • European Biomass Conference & Exhibition (https://www.eubce.com ) • Alga Europe (https://algaeurope.org) • Plant Based Summit (https://www.plantbasedsummit.com/who-visits) • Biomass Conference & Expo (http://www.biomassconference.com) • European Biotech Week (https://biotechweek.org) As a technology and manufacturing company we are constantly seeking expanding our capabilities, productivities and scale. Specialties we will need to compliment our team with are: Electrical Engineer, Biotechnologist, Mechanical Engineer, Software Engineer Big part of Drasys philosophy is to in-house design and manufacture our bioreactors and bioprocess systems. Thus, significant investment should be guided towards purchase of new manufacturing equipment including: 1. Industrial SLA 3D Printing Center 2. CNC Laser Cutter-Engraver 3. Automatic Injection Molder